Critical Comparison: Pathfinder Cell Therapy (OTCMKTS:PFND) versus Milestone Scientific (NYSE:MLSS)

Pathfinder Cell Therapy (OTCMKTS:PFND) and Milestone Scientific (NYSE:MLSS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Institutional & Insider Ownership

5.8% of Milestone Scientific shares are owned by institutional investors. 15.1% of Pathfinder Cell Therapy shares are owned by insiders. Comparatively, 24.8% of Milestone Scientific shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Pathfinder Cell Therapy and Milestone Scientific”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pathfinder Cell Therapy	N/A	N/A	N/A	N/A	N/A
Milestone Scientific	$9.83 million	5.95	-$6.93 million	($0.07)	-10.83

Pathfinder Cell Therapy has higher earnings, but lower revenue than Milestone Scientific.

Profitability

This table compares Pathfinder Cell Therapy and Milestone Scientific’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pathfinder Cell Therapy	N/A	N/A	N/A
Milestone Scientific	-54.87%	-60.78%	-40.80%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Pathfinder Cell Therapy and Milestone Scientific, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pathfinder Cell Therapy	0	0	0	0	0.00
Milestone Scientific	0	0	1	0	3.00

Milestone Scientific has a consensus target price of $1.25, indicating a potential upside of 64.95%. Given Milestone Scientific’s stronger consensus rating and higher possible upside, analysts plainly believe Milestone Scientific is more favorable than Pathfinder Cell Therapy.

Summary

Milestone Scientific beats Pathfinder Cell Therapy on 6 of the 9 factors compared between the two stocks.

About Pathfinder Cell Therapy

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.

About Milestone Scientific

Milestone Scientific Inc., a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. In addition, the company offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances, and disposable injection handpiece for the tactile control during the injection. Further, it provides CompuFlo Epidural, a computer-controlled anesthesia system for use in various medical applications. Additionally, the company offers company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Roseland, New Jersey.